Trabodenoson/latanoprost: Phase II started

Inotek began a double-blind, placebo-controlled, U.S. Phase II trial to compare once-daily trabodenoson/latanoprost given as a single eye drop in both eyes for 8 weeks vs. 0.0025% or 0.005% topical la...